Stomach Cancer Treatment Market to Grow with a CAGR of 14.84% through 2030
Growing prevalence of stomach cancer is expected to drive
the growth of global stomach cancer treatment in the forecast period,
2026-2030.
According to TechSci Research report, “Stomach
Cancer Treatment Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2030F”, the Global Stomach Cancer Treatment
Market was valued at USD 5.51 billion in 2024 and is expected to reach USD
12.64 billion by 2030 with a CAGR of 14.84% during the forecast
period. This can be ascribed to unhealthy lifestyle changes which also
incorporates smoking and alcoholism, etc., globally. Additionally, growing
number of cancer treatments centers with successful treatment plans, especially
in the developed countries in North America and Europe, are expected to create
lucrative opportunities for the market growth in coming years. Besides,
increasing research and development activities on cancer is further expected to
support the market growth. Similarly, growing approval and subsequent launches
of new drugs will further boost the market growth during the forecast period.
Also, rapid adoption of advanced diagnostic tools for the early detection of
stomach cancer is expected to create a significant growth during the forecast
period. Additionally, many pharmaceutical companies are investing for research
and development of novel drugs for the treatment of novel drugs and many
biosimilars of trastuzumab are entering the market which will further boost the
market growth during the forecast period.
However, high cancer therapy cost and less commercial
availability of drugs for the treatment of stomach cancer may slow down the
growth of global stomach cancer treatment market in the forecast period.
Similarly, high risks and complications associated with cancer therapy and
treatments, may hamper the global stomach cancer therapy treatment market
growth during the forecast period. Also, poor reimbursement scenario and lack
of insurance coverage for cancer therapy in emerging countries, can further restrict
the growth of global stomach cancer treatment market. Similarly, lesser
adoption of targeted therapy because of high costs may hamper the growth of the
global stomach cancer treatment market during the forecast period.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Stomach Cancer Treatment Market"
Global Stomach Cancer Treatment Market is segmented
into treatment type, cancer type, route of administration, drug class,
distribution channel, regional distribution and company.
Based on Treatment Type, Immunotherapy is currently the
fastest-growing treatment segment in the global stomach cancer therapy market.
In recent years, checkpoint inhibitors such as nivolumab (Opdivo) and
pembrolizumab (Keytruda) have demonstrated significant survival benefits,
particularly in advanced or metastatic gastric cancer with PD-L1 expression or
MSI-H (microsatellite instability-high) profiles. Moreover, immunotherapy is
gaining momentum in Asia-Pacific and Europe through government reimbursement and
inclusion in national cancer strategies. As clinical success stories accumulate
and prices begin to stabilize with competition, immunotherapy is expected to
continue its rapid uptake, making it the fastest-growing category within
stomach cancer treatments.
Based on the Region, The Asia Pacific region is currently
experiencing the fastest growth in the global stomach cancer treatment market,
driven by several interlinked factors. Rapidly expanding healthcare systems in
countries such as China, India, South Korea, and Japan are increasing the
number of patients diagnosed and treated, especially as endoscopy and pathology
services become more widely available. Governments across the region are taking
proactive steps: for instance, national screening programs in Japan and South
Korea have led to significantly higher early-stage diagnosis rates, while other
countries are expanding awareness campaigns and subsidizing cancer care through
public insurance schemes. Additionally, investments in cancer research and
infrastructure are accelerating the adoption of advanced therapies. Modern
treatment options like targeted therapies and immunotherapies are being
incorporated into standard care as regulatory bodies streamline approvals.
Meanwhile, rising incomes and broader health insurance coverage allow more
patients to access and afford these state-of-the-art treatments.
Demographic trends also play a pivotal role. With large
populations and rapidly aging societies, there is a growing elderly cohort
alongside improved detection of gastrointestinal cancers. Enhanced clinical
training and improved surgical capacity further bolster treatment access and
quality. As a result, Asia Pacific not only leads in increasing patient volumes
but is also poised to see significant growth in advanced therapeutic
deployments, making it the fastest-growing regional market for stomach cancer treatment.
Major companies operating in Global Stomach Cancer
Treatment Market are:
- Pfizer,
Inc.
- Novartis
AG
- Eli
Lilly and Company
- Bristol-Myers
Squibb Company
- Teva
Pharmaceutical Industries Ltd.
- F.
Hoffmann La Roche AG
- Mylan
N.V.
- Celltrion
Healthcare Co., Ltd
- Merck
KGaA
- Samsung
Bioepis
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“North America was expected to dominate in the
global stomach cancer treatment market due to increasing investments
in developing advanced treatment options for cancer among the population, .
Furthermore, increasing target patient population with untreated diseases,
along with different cancer types like stomach cancer are further contributing
towards rising stomach cancer treatment demands. Besides, the growing
prevalence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors
across the globe, the launch of novel therapies for metastatic stomach cancer,
availability of skilled professionals and early adoption of advanced treatments
for the treatment of stomach cancer in the region is further expected to create
lucrative opportunities for the market growth”, said Mr. Karan Chechi, Research
Director of TechSci Research, a research based global management consulting
firm.
“Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others), By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumors), By Route of Administration (Oral, Injectables), By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others), By Region and Competition, 2020-2030F”, has
evaluated the future growth potential of global stomach cancer
treatment market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in global stomach cancer
treatment market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com